BRPI0518209A - angiopoietin-2-specific binding agents - Google Patents
angiopoietin-2-specific binding agentsInfo
- Publication number
- BRPI0518209A BRPI0518209A BRPI0518209-3A BRPI0518209A BRPI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A
- Authority
- BR
- Brazil
- Prior art keywords
- specific binding
- binding agents
- angiopoietin
- antibodies
- disclosed
- Prior art date
Links
Abstract
AGENTES DE LIGAçãO ESPECìFICOS à ANGlOPOIETINA-2. São divulgados agentes de ligação especifica, tais como anti-corpos totalmente humanos, que se ligam à angiopoietina-2. Também divulgados são fragmentos de cadeia pesada, fragmentos de cadeia leve e CDRs dos anticorpos, bem como métodos de fabricação e uso dos anticorpos.ANGlOPOIETIN-2 SPECIFIC BINDING AGENTS. Specific binding agents, such as fully human antibodies, that bind to angiopoietin-2 are disclosed. Also disclosed are heavy chain fragments, light chain fragments and CDRs of antibodies, as well as methods of making and using antibodies.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62016104P | 2004-10-19 | 2004-10-19 | |
US10/982,440 US7658924B2 (en) | 2001-10-11 | 2004-11-04 | Angiopoietin-2 specific binding agents |
PCT/US2005/037911 WO2006045049A1 (en) | 2004-10-19 | 2005-10-19 | Angiopoietin-2 specific binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0518209A true BRPI0518209A (en) | 2008-11-04 |
Family
ID=39608222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0518209-3A BRPI0518209A (en) | 2004-10-19 | 2005-10-19 | angiopoietin-2-specific binding agents |
Country Status (10)
Country | Link |
---|---|
JP (2) | JP2008520188A (en) |
CN (1) | CN101495513B (en) |
BR (1) | BRPI0518209A (en) |
EA (1) | EA011866B1 (en) |
IL (1) | IL182279A0 (en) |
MA (1) | MA29015B1 (en) |
MX (1) | MX2007004247A (en) |
RU (2) | RU2404992C2 (en) |
SG (1) | SG156668A1 (en) |
ZA (1) | ZA200704020B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007004247A (en) * | 2004-10-19 | 2007-06-12 | Amgen Inc | Angiopoietin-2 specific binding agents. |
JO3182B1 (en) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
EA022546B1 (en) * | 2011-09-28 | 2016-01-29 | Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук | Method for inhibiting growth of ehrlich carcinoma in laboratory animal |
EP3628329B1 (en) * | 2011-09-30 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica) |
SG11201403792TA (en) * | 2012-01-23 | 2014-10-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
WO2014100834A1 (en) * | 2012-12-21 | 2014-06-26 | The Regents Of The University Of California | Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity |
MX368099B (en) * | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds. |
AR100270A1 (en) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | ANTIBODIES ANG2 |
JO3783B1 (en) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | Highly pure quinoline derivative and method for producing the same |
DK3263106T3 (en) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | PROCESS FOR SUPPRESSING BITTERNESS OF QUINOLINE DERIVATIVES |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
CN107801379B (en) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | Anticancer agent |
CN106512006A (en) * | 2016-07-25 | 2017-03-22 | 广州道瑞医药科技有限公司 | Application of ANGPT2 secretion inhibitor to preparation of medicine for treating hemangiomas |
CN106075448A (en) * | 2016-07-25 | 2016-11-09 | 广州道瑞医药科技有限公司 | ANGPT2 inhibitor is used for treating the application in angiomatous medicine in preparation |
CN109096368B (en) * | 2018-09-30 | 2021-07-20 | 华南理工大学 | Polypeptide with antioxidant and liver protecting activities, gene for encoding polypeptide, preparation method and application thereof |
CN113728004A (en) * | 2019-02-25 | 2021-11-30 | 药物抗体公司 | anti-Ang 2 antibodies and uses thereof |
CN112126671B (en) * | 2020-08-18 | 2021-08-31 | 中山大学附属第五医院 | Application of streptococcus agalactiae streptococcus agalactiae in treating endometriosis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1165115T3 (en) * | 1999-03-26 | 2003-09-22 | Regeneron Pharma | Modulation of vascular permeability by TIE2 receptor activators |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) * | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
DK2332523T4 (en) * | 2001-10-12 | 2022-02-21 | Aquestive Therapeutics Inc | Uniform films for rapid-dissolution dosage form containing taste-masking preparations |
MX2007004247A (en) * | 2004-10-19 | 2007-06-12 | Amgen Inc | Angiopoietin-2 specific binding agents. |
-
2005
- 2005-10-19 MX MX2007004247A patent/MX2007004247A/en active IP Right Grant
- 2005-10-19 CN CN200580043569.5A patent/CN101495513B/en not_active Expired - Fee Related
- 2005-10-19 BR BRPI0518209-3A patent/BRPI0518209A/en not_active IP Right Cessation
- 2005-10-19 EA EA200700876A patent/EA011866B1/en not_active IP Right Cessation
- 2005-10-19 SG SG200907008-7A patent/SG156668A1/en unknown
- 2005-10-19 JP JP2007538066A patent/JP2008520188A/en active Pending
- 2005-10-19 RU RU2007118670/13A patent/RU2404992C2/en not_active IP Right Cessation
-
2007
- 2007-03-28 IL IL182279A patent/IL182279A0/en unknown
- 2007-05-11 MA MA29892A patent/MA29015B1/en unknown
- 2007-05-18 ZA ZA200704020A patent/ZA200704020B/en unknown
-
2010
- 2010-08-05 RU RU2010132956/10A patent/RU2010132956A/en not_active Application Discontinuation
-
2011
- 2011-03-30 JP JP2011075243A patent/JP2011207882A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MA29015B1 (en) | 2007-11-01 |
SG156668A1 (en) | 2009-11-26 |
JP2008520188A (en) | 2008-06-19 |
CN101495513B (en) | 2014-08-06 |
RU2010132956A (en) | 2012-02-10 |
EA011866B1 (en) | 2009-06-30 |
IL182279A0 (en) | 2007-07-24 |
MX2007004247A (en) | 2007-06-12 |
JP2011207882A (en) | 2011-10-20 |
CN101495513A (en) | 2009-07-29 |
EA200700876A1 (en) | 2007-10-26 |
ZA200704020B (en) | 2008-06-25 |
RU2007118670A (en) | 2008-12-27 |
RU2404992C2 (en) | 2010-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0518209A (en) | angiopoietin-2-specific binding agents | |
CY1124802T1 (en) | SCLEROSTEIN BINDING FACTORS | |
PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
RS28904A (en) | Angiopoietin-2 specific binding agents | |
EA200800812A1 (en) | Antibody Anti-CD3 Compositions | |
EA201001335A1 (en) | ANTIBODIES DIRECTED AGAINST ANGIOPOETHINA-1 AND ANGIOPOETINA-2 AND THEIR APPLICATION | |
EA201070888A1 (en) | ANTIBODIES AND THEIR DERIVATIVES | |
CR10530A (en) | ANTI-DLLA4 ANTIBODIES AND METHODS THAT USE THEM | |
EA201101593A1 (en) | COMPOSITIONS AND METHODS INTENDED FOR THE DIRECTED IMPACT OF ANTIBODIES ON PROTEIN C3b COMPLEMENT SYSTEMS | |
EA200600065A3 (en) | HYDROPHOBIC COMPOSITION AND BULK MATERIALS, THEIR APPLICATION | |
EA200970477A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF APPLICATION | |
EA200801679A1 (en) | COMPOSITIONS AND METHODS OF APPLICATION OF ANTIBODIES TO DICKKOPF-1 AND / OR -4 | |
PH12014501927A1 (en) | Antibodies to matrix metalloproteinase 9 | |
BR112015014751A2 (en) | human anti-tau antibodies | |
EA201070695A1 (en) | MOLECULES OF HUMANIZED ANTIBODIES SPECIFIC TO IL-31 | |
ATE512986T1 (en) | ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS AND THEIR USE | |
CO6280541A2 (en) | MONOCLONAL ANTIBODIES OR FRAGMENTS OF THE SAME THAT JOIN THE HXAN RECEIVER OX40 | |
EA200400526A1 (en) | AGENTS SPECIFICALLY CONNECTING WITH HUMAN ANGIOPOETIN-2 | |
MY150400A (en) | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof | |
EA200970210A1 (en) | PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS | |
ATE505489T1 (en) | TGF-BETA-1 SPECIFIC ANTIBODIES | |
HN2005029978A (en) | FORMULATIONS | |
PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
BR112012009846B8 (en) | in vitro method and kit for detecting an ige isotype anti-drug antibody, and use of an ige isotype anti-drug antibody in the treatment of an ige-mediated disorder | |
ATE504602T1 (en) | BINDING PROTEINS SPECIFIC TO HUMAN MATRIPTASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |